Mirabegron 25 mg for Treatment of Primary Nocturnal Enuresis
Launched by BENHA UNIVERSITY · Nov 8, 2022
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a medication called mirabegron, which is being tested to see if it can help treat primary nocturnal enuresis, commonly known as bedwetting. The goal is to compare the effectiveness and safety of mirabegron with another medication called desmopressin and also with behavioral therapy, which involves strategies to help manage bedwetting. The trial is currently recruiting participants aged 18 to 26 and 54 to 78, regardless of gender.
To be eligible for the study, participants must have primary nocturnal enuresis, meaning they wet the bed without a known medical cause, and they should not experience daytime wetting. They need to have wet the bed at least four times in the last month and should have normal medical examinations. If you or someone you know is interested in participating, they can expect to receive either the mirabegron medication, desmopressin, or behavioral therapy during the study. This trial aims to find effective treatments for bedwetting, which can be an important issue for many individuals and families.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • primary nocturnal enuresis,
- • negligible daytime wetting,
- • wet at least 4 times over 4 weeks
- • normal clinical examination with no neurological or urological cause for the enuresis
- Exclusion Criteria:
- • secondary enuresis, polysymptomatic
- • neurologic bladder, neurological disorders,
- • urinary incontinence disorders
- • previous anti NE drugs.
About Benha University
Benha University, a leading institution in Egypt, is dedicated to advancing medical research and innovation through rigorous clinical trials. With a strong emphasis on multidisciplinary collaboration, the university aims to enhance healthcare outcomes by exploring novel therapeutic approaches and interventions. Its state-of-the-art facilities and commitment to ethical research practices ensure that all trials are conducted with the highest standards of integrity and scientific rigor. Benha University actively contributes to the global medical community by fostering partnerships and disseminating findings that can improve patient care and inform public health policies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Banhā, Qaliopia, Egypt
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials